sh pharma announced that the subsidiary Xinyi Wanxiang's Alphacalcidol active pharmaceutical ingredient recently received the "Chemical raw materials market application approval notice" issued by the National Medical Products Administration. The drug has been approved for production. Alphacalcidol is mainly used to treat calcium metabolic disorders caused by insufficient endogenous 1,25-dihydroxy vitamin D3 production.
上海医药：阿法骨化醇原料药上市申请获得批准
sh pharma: Approval obtained for the market application of Alphacalcidol API.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated